AmeriPath grows GI diag services, names directors
AmeriPath (Palm Beach Gardens, Florida), a national provider of cancer diagnostics, genomics, and related information services, reported the expansion of its GI diagnostic services in the Northeast.
A. Brian West, MD, the company's recently appointed director of gastrointestinal pathology services, AmeriPath New York, will head the development and expansion of AmeriPath's GI specialty services in the Northeast region. West is a nationally renowned pathologist who has specialized in the diagnosis and treatment of GI disease for more than 18 years. He has served in numerous prestigious appointments in both the GI clinical and academic service arenas.
Susan Kornacki, MD, who joined AmeriPath in October 2005 as part of its expanding team of dedicated pathologists specializing in GI pathology and digestive disease, has been appointed associate director of GI Pathology Services, AmeriPath New York. Kornacki has held prestigious appointments in the GI clinical and academic service arenas.
AmeriPath New York Gastrointestinal Diagnostics will focus on providing primary GI histological services, consultations on difficult cases, and esoteric tests to assist physicians in the diagnosis and management of GI disease.
Focus offers genetics interpretive service
Focus Diagnostics (Herndon, Virginia) reported the release of GenomEx, a new genetics interpretive service that provides personalized interpretation and comprehensive reporting for complex genetic carrier testing. The company said the service is ideal for hospitals and commercial laboratories capable of conducting genetics testing that do not have access to a board-certified clinical molecular geneticist to provide personalized revised risk assessments and clinical consultation.
The first GenomEx interpretive service is for cystic fibrosis. Interpretive services for other genetic diseases will be added in the future.
The platform-neutral GenomEx CF interpretive service combines personal risk information with mutation/variant test results, provided by the performing laboratory, to generate personalized revised carrier risk assessment reports that are reviewed and released by a board-certified clinical molecular geneticist. Information is transmitted via Focus Link, a secure web-based test ordering and result delivery system.
Minrad International now trading on Amex
Minrad International (Buffalo, New York) reported that its common stock is now listed on the American Stock Exchange under the ticker symbol BUF.
Minrad describes itself as an acute-care company with real-time image guidance, anesthesia and analgesia product lines. The company also manufactures generic inhalation anesthetics for use in connection with human and veterinary surgical procedures.
The company also is developing a drug/drug delivery system for conscious sedation, which, similar to nitrous oxide in dental surgery, provides a patient with pain relief without loss of consciousness.